<?xml version="1.0" encoding="UTF-8"?>
<ref id="B15-pathogens-08-00216">
 <label>15.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>García</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Bernaldo de Quirós</surname>
    <given-names>J.C.L.</given-names>
   </name>
   <name>
    <surname>Gómez</surname>
    <given-names>C.E.</given-names>
   </name>
   <name>
    <surname>Perdiguero</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Nájera</surname>
    <given-names>J.L.</given-names>
   </name>
   <name>
    <surname>Jiménez</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>García-Arriaza</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Guardo</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Pérez</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Díaz-Brito</surname>
    <given-names>V.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)</article-title>
  <source>Vaccine</source>
  <year>2011</year>
  <volume>29</volume>
  <fpage>8309</fpage>
  <lpage>8316</lpage>
  <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.08.098</pub-id>
  <pub-id pub-id-type="pmid">21907749</pub-id>
 </element-citation>
</ref>
